Last reviewed · How we verify
NCT03415659
Phase I Clinical Study of HWH340 Tablet in Patients With Advanced Solid Tumors
Phase 1 trial testing HWH340 tablet in Advanced Solid Tumors in 85 participants. Status unknown.
30 March 2021
Quick facts
| Lead sponsor | Hubei Biological Medicine Industrial Technology Institute Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 85 |
| Start date | 5 March 2018 |
| Primary completion | 30 March 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- HWH340 tablet — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
- HRD — all drugs for HRD →
- BRCA Mutation — all drugs for BRCA Mutation →
Sponsor
Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
Who can join
Adults 18 to 70, any sex, with Advanced Solid Tumors or HRD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, dose-escalation/dose-expansion, phase I clinical trial study to investigate the safety, tolerability, and efficacy of HWH340. In addition, the pharmacokinetic characteristics will also be investigated. Three parts are included in this study.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
Maccaroni E, Giampieri R, Lenci E, Scortichini L, et al · · 2021 · cited 13× · PMID 34367929 · DOI 10.5306/wjco.v12.i7.565 -
Antitumor activity and structure-activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors.
Yang C, Shang Y, Li X, Li J, et al · · 2026 · PMID 41395847 · DOI 10.1080/14756366.2025.2598478
Verify or expand the search:
- PubMed search for NCT03415659
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03415659 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hubei Biological Medicine Industrial Technology Institute Co., Ltd.
- Last refreshed: 17 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03415659.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing